Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to demonstrate the effect of Auryxia, when used as the primary
phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent
and intravenous iron as well as on the laboratory parameters indicative of phosphate and
anemia management.